Navigation Links
Blizzard, McCarthy & Nabers Launches ReglanJustice.com
Date:3/9/2010

Informs Public of Serious Risks Associated with Use of Reglan and Metoclopramide: Provides Solutions for Legal Recourse

HOUSTON, March 9 /PRNewswire-USNewswire/ -- Blizzard, McCarthy & Nabers, one of the nation's leading pharmaceutical litigation firms is proud to announce the launch of ReglanJustice.com, an educational website aimed at informing consumers of the risks associated with the use of the drug Reglan, and its generic form, metoclopramide.  As a resource for the millions of Americans who use this drug, ReglanJustice.com is regularly updated with the latest news and medical information surrounding the medication and its causal link to debilitative movement disorders.

Long-term use of Reglan and generic forms of metoclopramide has been linked to Tardive Dyskinesia, a serious involuntary and repetitive movement disorder that is often irreversible. A recent study cited by the FDA, reports the prevalence of Tardive Dyskinesia at 20 percent among patients treated with Reglan for at least 12 weeks. In February 2009, the FDA issued a Black Box warning against continued use of Reglan to treat gastrointestinal disorders.

ReglanJustice.com is meant to provide consumers with the critical information denied to them by the pharmaceutical manufacturers marketing these drugs.  For those consumers who have already been disabled by these products, ReglanJustice.com provides an avenue to seek legal redress.  Corporations that operate with an eye on the bottom line rather than the safety of their consumers must be held accountable for their actions.  For more information, visit www.reglanjustice.com.

"As attorneys, we've seen first hand the damage that can be done by these powerful and dangerous drugs," said Scott Nabers, partner at Blizzard, McCarthy & Nabers.  "Consumers were misinformed about the risks associated with this product and many have been permanently disabled.  It is our hope that this website will provide consumers with critical information so that future patients can avoid these troubling side effects."

In January, the firm launched www.denturecreamjustice.com to provide information and avenues to legal recourse for consumers poisoned by zinc in denture cream.

Blizzard, McCarthy & Nabers, LLP, one of the nation's leading pharmaceutical litigation firms, represents thousands of clients harmed by dangerous drugs and medical devices and has taken on some of the world's largest corporations, including Bristol-Myers, GlaxoSmithKline, Merck, Pfizer and Dow Chemical. 

SOURCE Blizzard, McCarthy & Nabers, LLP

Back to top

RELATED LINKS
http://reglanjustice.com/

'/>"/>

SOURCE Blizzard, McCarthy & Nabers, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
2. Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
3. P&M Corporate Finance and Robin Young Announce 2010 Spine Technology Summit
4. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
5. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
6. UBM Announces Plans for Japan Pharma & Bio Events
7. Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists
8. Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review
9. China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Aurora Womens Pavilion Center for Sexual Health & Wellness Receives Grant to Treat Vulvar Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):